ClinicalTrials.gg
Enrolling by invitationNCT05678491Updated Oct 21, 2026

Endoscopic Treatment of Gastroesophageal Reflux Disease

An interventional study of Endoscopic mucosal band ligation in Gastro Esophageal Reflux Disease, sponsored by St. Olavs Hospital. Enrolling by invitation at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by St. Olavs Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 21, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Gastroesophageal Reflux with a site in Norway — 3 open to participants now, 4 under way, none of them phase 3. Gastroesophageal Reflux · Norway.

Planned enrollment
12th of 12
12 · median 297
Started
2025
the only one that year
No phase
4 of 15
2 open now
Registered
13th of 15
by date
Lead sponsor
1 of 15
St. Olavs Hospital

Among the 15 studies in Gastroesophageal Reflux with a site in Norway, this one is the 12th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 4 with no phase, and was the 13th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

3 of the 15 studies in Gastroesophageal Reflux with a site in Norway are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Gastroesophageal Reflux with a site in Norway, or all of them as a file.
02

Study summary

Gastroesophageal reflux disease (GERD) occurs when stomach acid repeatedly flows back into the tube connecting your mouth and stomach (esophagus). This backwash (acid reflux) can irritate the inner lining of the esophagus. This is a particular problem after surgery to reduce obesity called gastric sleeve resection.

The goal of this small clinical trial is to examine the effect of endoscopic treatment of GERD by mucosal band ligation. The main questions it aims to answer are:

  • Does the treatment affect gastroesophageal reflux assessed by measuring gastroesophageal reflux
  • Does the treatment affect gastroesophageal reflux symptoms and ability to stop treatment with medication commonly used (proton pump inhibitors)

Participants (n=12) will be asked to undergo 24 h reflux examination and report symptoms of GERD. Suitable patients will be offered endoscopic treatment with band ligation of the inner lining of the lower esophagus and upper part of the stomach. The effects will be assessed three and six months after the procedure.

Read the detailed description

Gastroesophageal reflux disease (GERD) is very common after gastric sleeve resection and many patients are dependent on daily use of proton pump inhibitors (PPIs). The goal of this small clinical trial is to examine the effect of endoscopic treatment of GERD by mucosal band ligation.

Patients (n=12) with GERD satisfying inclusion and exclusion criteria will be invited to participate and the degree of gastroesophageal reflux will be assessed before treatment, and three and six months after the procedure. The results of the trial will be used to plan a larger study.

03

Conditions studied

  • Gastro Esophageal Reflux Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (all criteria must be fulfilled):

  • Previous gastric sleeve resection
  • GERD. GERD must be diagnosed by either endoscopic esophagitis or esophageal pH measurement with DeMeester score > 14.72 and pH \<4 more than 4% of a 24-h period and symptom association probability (SAP) > 95%
  • Subjective insufficient symptom control with PPI therapy once daily or intolerance to PPI or desire to stop PPI treatment and therefore willingness to undergo endoscopic treatment.

Exclusion Criteria:

  • Hiatal hernia > 5 cm
  • Age \< 18_years
  • Preexisting esophageal stricture
  • Gastric stricture \< 2 cm in diameter
  • Anti-coagulant medication
  • Use of inhibitors other than acetylsalicylic acid
  • Manometric indication of motility disorder
  • Connective tissue diseases
  • > 35
  • Liver cirrhosis
  • Coronary heart disease
  • Other significant comorbidity
  • Indication for long-term PPI use other than GERD
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Endoscopic mucosal band ligation

    All 12 patients with GERD will undergo the same procedure. Multiple rubber bands will be used to ligate mucosa in the gastroesophageal junction and cardia in 3/4 of the circumference.

    Other: Endoscopic mucosal band ligation

Interventions

  • OtherEndoscopic mucosal band ligation

    The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.

06

What researchers measure

Primary outcomes

  1. Change from baseline esophageal 24 hour pH/impedance at 3 months

    Esophageal pH/impedance will be measured by a catheter left in place for 24 hours

    Time frame: 3 months

  2. Change from baseline esophageal 24 hour pH/impedance at 6 months

    Esophageal pH/impedance will be measured by a catheter left in place for 24 hours

    Time frame: 6 months

  3. Change from baseline symptoms of gastroesophageal reflux at 3 months

    GERD Q score. Gastroesophageal reflux disease Questionnaire with minimum value 0 (no symptoms) and maximum value 18 (severe symptoms)

    Time frame: 3 months

  4. Change from baseline symptoms of gastroesophageal reflux at 6 months

    GERD Q score. Gastroesophageal reflux disease Questionnaire with minimum value 0 (no symptoms) and maximum value 18 (severe symptoms)

    Time frame: 6 months

  5. Change from baseline in use of proton pump inhibitors (PPI) at 3 months

    PPI use (number of days PPI was used during the period 7-14 days before the 3 months visit)

    Time frame: 3 months

  6. Change from baseline in use of proton pump inhibitors (PPI) at 6 months

    PPI use (number of days PPI was used during the period 7-14 days before the 6 months visit)

    Time frame: 6 months

  7. Adverse events during the study period of 6 months

    Adverse events or complications of the treatment will be registered during the study period

    Time frame: 6 months

Secondary outcomes

  1. Change from baseline in dysphagia at 3 months

    Dysphagia assessed by Marks score. The minimum value is 0 (no dysphagia) and the maximum value is 6 (can not eat, which is the most severe symptom).

    Time frame: 3 months

  2. Change from baseline in dysphagia at 6 months

    Dysphagia assessed by Marks score. The minimum value is 0 (no dysphagia) and the maximum value is 6 (can not eat, which is the most severe symptom).

    Time frame: 6 months

  3. Change from baseline in Hills flap valve at 3 months

    The Hills flap valve assessed during endoscopy. Minimum value is 1 (good function) and the maximum value is 4 (poor function)

    Time frame: 3 months

  4. Change from baseline in Hills flap valve at 6 months

    The Hills flap valve assessed during endoscopy. Minimum value is 1 (good function) and the maximum value is 4 (poor function)

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The plan is to publish all relevant data from this small trial with the detail level permitted by the local approval. Further data sharing will not be planned for.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.

Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's planned 23 months is below that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jul 2026 → Jul 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2023
First posted
Jan 10, 2023
StartActual
Aug 1, 2025
Primary completionEst.
Jul 1, 2027was Jul 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Jul 1, 2027
Oct 21, 2026
Study completion
Dec 2026→Dec 2027
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Jul 2026→Jul 1, 2027
    Study completion Dec 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05678491
Lead sponsor
St. Olavs Hospital
Responsible party
Sponsor
First posted
Jan 10, 2023
Start date
Aug 1, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Gunnar Qvigstad, MD, PhD
study director · St. Olavs Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion